SAN JOSE -
Conference details
Presentation:
Conference registration: Available on the conference website
1x1 meetings: Open to all investors upon conference registration
The presentation date and time are subject to change. Participants should refer to the final program agenda for up-to-date information.
About
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words 'believes,' 'expects,' 'intends,' 'plans,' 'anticipates,' 'likely,' 'will' and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in 'Item 1A - Risk Factors' and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10- Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward- looking statements when evaluating the information presented in this press release.
Contact:
Email: mcatelani@anixa.com
Tel: 408-708-9808
(C) 2024 Electronic News Publishing, source